Local sustained delivery of bupivacaine HCL from a new castor oil-based nanoemulsion system

Heni Rachmawati (Corresponding Author), Yang Aryani Arvin, Sukmadjaja Asyarie, Kusnandar Anggadiredja, Raymond Rubianto Tjandrawinata, Gert Storm

Research output: Contribution to journalArticleAcademicpeer-review

2 Citations (Scopus)

Abstract

Bupivacaine HCl (1-butyl-2′,6′-pipecoloxylidide hydrochloride), an amide local anesthetic compound, is a local anesthetic drug utilized for intraoperative local anesthesia, post-operative analgesia and in the treatment of chronic pain. However, its utility is limited by the relative short duration of analgesia after local administration (approximately 9 h after direct injection) and risk for side effects. This work is aimed to develop a nanoemulsion of bupivacaine HCl with sustained local anesthetics release kinetics for improved pain management, by exhibiting extended analgesic action and providing reduced peak levels in the circulation to minimize side effects. Herein, biodegradable oils were evaluated for use in nanoemulsions to enable sustained release kinetics of bupivacaine HCl. Only with castor oil, a clear and stable nanoemulsion was obtained without the occurrence of phase separation over a period of 3 months. High loading of bupivacaine HCl into the castor oil-based nanoemulsion system was achieved with about 98%entrapment efficiency and the resulting formulation showed high stability under stress conditions (accelerated stability test) regarding changes in visual appearance, drug content, and droplet size. We show herein that the in vitro release and in vivo pharmacokinetic profiles as well as pharmacodynamic outcome (pain relief test) after subcutaneous administration in rats correlate well and clearly demonstrate the prolonged release and extended duration of activity of our novel nanoformulation. In addition, the lower Cmax value achieved in the blood compartment suggests the possibility that the risk for systemic side effects is reduced. We conclude that castor oil-based nanomulsion represents an attractive pain treatment possibility to achieve prolonged local action of bupivacaine HCl.

Original languageEnglish
Pages (from-to)515-524
Number of pages10
JournalDrug delivery and translational research
Volume8
Issue number3
Early online date7 Mar 2018
DOIs
Publication statusPublished - Jun 2018

Fingerprint

Castor Oil
Bupivacaine
Local Anesthetics
Analgesia
Pain
Local Anesthesia
Pain Management
Amides
Chronic Pain
Analgesics
Anesthetics
Oils
Pharmacokinetics
Injections
Therapeutics
Pharmaceutical Preparations

Keywords

  • UT-Hybrid-D
  • Bupivacaine HCl
  • Cardiotoxic
  • Castor oil
  • Local analgesic
  • Nanoemulsion
  • Prolonged release
  • Amide local anesthetic

Cite this

Rachmawati, Heni ; Arvin, Yang Aryani ; Asyarie, Sukmadjaja ; Anggadiredja, Kusnandar ; Tjandrawinata, Raymond Rubianto ; Storm, Gert. / Local sustained delivery of bupivacaine HCL from a new castor oil-based nanoemulsion system. In: Drug delivery and translational research. 2018 ; Vol. 8, No. 3. pp. 515-524.
@article{3de4c5bb527449f79d02c35b50b003fd,
title = "Local sustained delivery of bupivacaine HCL from a new castor oil-based nanoemulsion system",
abstract = "Bupivacaine HCl (1-butyl-2′,6′-pipecoloxylidide hydrochloride), an amide local anesthetic compound, is a local anesthetic drug utilized for intraoperative local anesthesia, post-operative analgesia and in the treatment of chronic pain. However, its utility is limited by the relative short duration of analgesia after local administration (approximately 9 h after direct injection) and risk for side effects. This work is aimed to develop a nanoemulsion of bupivacaine HCl with sustained local anesthetics release kinetics for improved pain management, by exhibiting extended analgesic action and providing reduced peak levels in the circulation to minimize side effects. Herein, biodegradable oils were evaluated for use in nanoemulsions to enable sustained release kinetics of bupivacaine HCl. Only with castor oil, a clear and stable nanoemulsion was obtained without the occurrence of phase separation over a period of 3 months. High loading of bupivacaine HCl into the castor oil-based nanoemulsion system was achieved with about 98{\%}entrapment efficiency and the resulting formulation showed high stability under stress conditions (accelerated stability test) regarding changes in visual appearance, drug content, and droplet size. We show herein that the in vitro release and in vivo pharmacokinetic profiles as well as pharmacodynamic outcome (pain relief test) after subcutaneous administration in rats correlate well and clearly demonstrate the prolonged release and extended duration of activity of our novel nanoformulation. In addition, the lower Cmax value achieved in the blood compartment suggests the possibility that the risk for systemic side effects is reduced. We conclude that castor oil-based nanomulsion represents an attractive pain treatment possibility to achieve prolonged local action of bupivacaine HCl.",
keywords = "UT-Hybrid-D, Bupivacaine HCl, Cardiotoxic, Castor oil, Local analgesic, Nanoemulsion, Prolonged release, Amide local anesthetic",
author = "Heni Rachmawati and Arvin, {Yang Aryani} and Sukmadjaja Asyarie and Kusnandar Anggadiredja and Tjandrawinata, {Raymond Rubianto} and Gert Storm",
note = "Springer deal",
year = "2018",
month = "6",
doi = "10.1007/s13346-018-0497-5",
language = "English",
volume = "8",
pages = "515--524",
journal = "Drug delivery and translational research",
issn = "2190-393X",
publisher = "Springer",
number = "3",

}

Local sustained delivery of bupivacaine HCL from a new castor oil-based nanoemulsion system. / Rachmawati, Heni (Corresponding Author); Arvin, Yang Aryani; Asyarie, Sukmadjaja; Anggadiredja, Kusnandar; Tjandrawinata, Raymond Rubianto; Storm, Gert.

In: Drug delivery and translational research, Vol. 8, No. 3, 06.2018, p. 515-524.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Local sustained delivery of bupivacaine HCL from a new castor oil-based nanoemulsion system

AU - Rachmawati, Heni

AU - Arvin, Yang Aryani

AU - Asyarie, Sukmadjaja

AU - Anggadiredja, Kusnandar

AU - Tjandrawinata, Raymond Rubianto

AU - Storm, Gert

N1 - Springer deal

PY - 2018/6

Y1 - 2018/6

N2 - Bupivacaine HCl (1-butyl-2′,6′-pipecoloxylidide hydrochloride), an amide local anesthetic compound, is a local anesthetic drug utilized for intraoperative local anesthesia, post-operative analgesia and in the treatment of chronic pain. However, its utility is limited by the relative short duration of analgesia after local administration (approximately 9 h after direct injection) and risk for side effects. This work is aimed to develop a nanoemulsion of bupivacaine HCl with sustained local anesthetics release kinetics for improved pain management, by exhibiting extended analgesic action and providing reduced peak levels in the circulation to minimize side effects. Herein, biodegradable oils were evaluated for use in nanoemulsions to enable sustained release kinetics of bupivacaine HCl. Only with castor oil, a clear and stable nanoemulsion was obtained without the occurrence of phase separation over a period of 3 months. High loading of bupivacaine HCl into the castor oil-based nanoemulsion system was achieved with about 98%entrapment efficiency and the resulting formulation showed high stability under stress conditions (accelerated stability test) regarding changes in visual appearance, drug content, and droplet size. We show herein that the in vitro release and in vivo pharmacokinetic profiles as well as pharmacodynamic outcome (pain relief test) after subcutaneous administration in rats correlate well and clearly demonstrate the prolonged release and extended duration of activity of our novel nanoformulation. In addition, the lower Cmax value achieved in the blood compartment suggests the possibility that the risk for systemic side effects is reduced. We conclude that castor oil-based nanomulsion represents an attractive pain treatment possibility to achieve prolonged local action of bupivacaine HCl.

AB - Bupivacaine HCl (1-butyl-2′,6′-pipecoloxylidide hydrochloride), an amide local anesthetic compound, is a local anesthetic drug utilized for intraoperative local anesthesia, post-operative analgesia and in the treatment of chronic pain. However, its utility is limited by the relative short duration of analgesia after local administration (approximately 9 h after direct injection) and risk for side effects. This work is aimed to develop a nanoemulsion of bupivacaine HCl with sustained local anesthetics release kinetics for improved pain management, by exhibiting extended analgesic action and providing reduced peak levels in the circulation to minimize side effects. Herein, biodegradable oils were evaluated for use in nanoemulsions to enable sustained release kinetics of bupivacaine HCl. Only with castor oil, a clear and stable nanoemulsion was obtained without the occurrence of phase separation over a period of 3 months. High loading of bupivacaine HCl into the castor oil-based nanoemulsion system was achieved with about 98%entrapment efficiency and the resulting formulation showed high stability under stress conditions (accelerated stability test) regarding changes in visual appearance, drug content, and droplet size. We show herein that the in vitro release and in vivo pharmacokinetic profiles as well as pharmacodynamic outcome (pain relief test) after subcutaneous administration in rats correlate well and clearly demonstrate the prolonged release and extended duration of activity of our novel nanoformulation. In addition, the lower Cmax value achieved in the blood compartment suggests the possibility that the risk for systemic side effects is reduced. We conclude that castor oil-based nanomulsion represents an attractive pain treatment possibility to achieve prolonged local action of bupivacaine HCl.

KW - UT-Hybrid-D

KW - Bupivacaine HCl

KW - Cardiotoxic

KW - Castor oil

KW - Local analgesic

KW - Nanoemulsion

KW - Prolonged release

KW - Amide local anesthetic

UR - http://www.scopus.com/inward/record.url?scp=85054974793&partnerID=8YFLogxK

U2 - 10.1007/s13346-018-0497-5

DO - 10.1007/s13346-018-0497-5

M3 - Article

VL - 8

SP - 515

EP - 524

JO - Drug delivery and translational research

JF - Drug delivery and translational research

SN - 2190-393X

IS - 3

ER -